Genetic screening developed by Illumina Inc for Down syndrome and Edwards syndrome led to more accurate diagnosis.

The company-funded study suggested that it could support the expansion of the screening to expectant mothers beyond only those considered at high risk for having babies with Down and Edwards syndromes.
“The major advantage of using cfDNA testing was the reduction in rates of false positive results. The findings suggest that cfDNA testing merits serious consideration as a primary screening method for fetal autosomal aneuploidy”, lead researcher Diana Bianchi of Tufts Medical Center in Boston said.
Source-Medindia